April 21, 2009 / 8:38 AM / 10 years ago

Boehringer Ingelheim sees sales outpacing market

INGELHEIM, Germany, April 21 (Reuters) - The weak dollar and higher spending on research pushed operating profit at Boehringer Ingelheim down 6 percent to 1.98 billion euros ($2.56 billion) in 2008, Germany’s second-biggest drugs group said on Tuesday.

Net profit fell 21 percent to 1.43 billion as research spending rose 11 percent, the family-controlled group said.

It forecast sales of its prescription drugs would grow by a single-digit percentage rate this year, faster than the global market.

Reporting by Frank Siebelt

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below